Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA says Zicam enforcement routine

This article was originally published in The Tan Sheet

Executive Summary

FDA says simultaneously announcing a consumer safety alert and sending a warning letter to Matrixx Initiatives about the risks of Zicam zinc-containing intranasal homeopathic products due to potential loss of smell is not an unusual action, as some industry stakeholders suggest. Center for Drug Evaluation and Research officials say "warning letters are issued to achieve voluntary compliance," such as the agency's June 16 communication with Matrixx about Zicam. "When it is consistent with the public protection responsibilities of the agency and depending on the nature of the violation, it is FDA's practice to give firms an opportunity to take voluntary and prompt corrective actions before it initiates an enforcement action," CDER said July 13. Matrixx voluntarily recalled the products the same day it received the warning letter (1"The Tan Sheet" June 29, 2009)

You may also be interested in...



FDA Uses "Unusual" Action To Get Matrixx's Zicam Off The Market

In a rare action, FDA simultaneously alerted consumers not to use Matrixx Initiatives' intranasal Zicam products because of potential safety problems and warned Matrixx to remove the products from market without first consulting with the firm

American Injectables $10m Investment Bolsters Domestic Production

American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.

EMA Consults On Using Registry Studies As RWE Source

A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel